Skip to content

Diminished the postoperative delirium in patients following microvascular decompression by Huperzine-A injection: a single-center, prospective, double-blinded, randomized, controlled trial

Diminished the postoperative delirium in patients following microvascular decompression by Huperzine-A injection: a single-center, prospective, double-blinded, randomized, controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033906
Enrollment
Unknown
Registered
2020-06-16
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative delirium

Interventions

control group:normal saline

Sponsors

Xinhua Hospital Affilated to Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with age >= 65 years old, regardless of gender; 2. Patients who meet the indication of MVD operation under general anesthesia; 3. Agree to participate in the trial, and the patient or his guardian with legal significance shall sign the informed consent before the trial.

Exclusion criteria

Exclusion criteria: 1. Patients with MMSE score < 23; 2. Patients with liver and kidney dysfunction; 3. Patients with central nervous system diseases; 4. Patients who have a history of mental illness and take sedatives and antidepressants for a long time; 5. Patients with a history of alcohol and drug abuse; 6. Patients with serious systemic diseases, especially circulatory diseases, such as myocardial infarction, heart failure, unstable angina, history of sinobradycardia; 7. Patients who can not tolerate the experiment or cooperate with the examination due to various reasons, various aphasia, audio-visual dysfunction, etc; 8. Patients known to be allergic to huperzine A; 9. Patients who participated in other clinical trials within 3 months before the start of this study.

Design outcomes

Primary

MeasureTime frame
Delirium rating scale;

Secondary

MeasureTime frame
CAM-ICU;MMSE;NPI;

Countries

China

Contacts

Public ContactShiting Li

Xinhua Hospital Affiliated to School of Medicine, Shanghai Jiaotong University

lishiting@xinhuamed.com.cn+86 13701625911

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026